AstraZeneca stock falls after FDA panel votes against new cancer drug

by | May 1, 2026 | news, Top News

Spread the love
The advisory panel wasn’t convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments